INmune Bio, Inc. (INMB) Stock Score, Valuation & Financial Research

INmune Bio, Inc. is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for INMB

INmune Bio, Inc. does not currently have a complete Wall Street Score. The stored market price is USD 1.87. These figures are a research snapshot, not a buy or sell recommendation.

What INmune Bio, Inc. does

INmune Bio, Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies. Its primary objective is to harness the body's innate immune system to combat various illnesses. The company is actively engaged in developing and bringing to market therapeutic candidates designed to address a spectrum of conditions such as blood cancers, solid tumors, and chronic inflammatory diseases. Its pipeline features key development programs including: INKmune: Aimed at treating women suffering from relapsed or refractory ovarian carcinoma and individuals diagnosed with high-risk myelodysplastic syndrome. INB03: An immunotherapy targeting patients with both hematologic malignancies and solid tumors. XPro1595: Under development for the treatment of Alzheimer's disease. INmune Bio holds licensing agreements with entities including Xencor, Inc., Immune Ventures, LLC, the University of Pittsburgh, and University College London. Established in 2015, INmune Bio is headquartered in Boca Raton, Florida.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

INmune Bio is a clinical-stage biotechnology company that generates revenue primarily through research and development collaborations and licensing agreements. As a clinical-stage entity, it does not yet have commercialized products and relies on capital raises and strategic partnerships to fund the development of its immunotherapies.

Products and services

The company develops a pipeline of product candidates designed to reprogram the innate immune system, including INKmune, INB03, and XPro, targeting cancer, neurodegenerative, and inflammatory diseases.

Brands and product families

XPro — A product candidate targeting chronic inflammation. Source
INKmune — A product candidate for cancer immunotherapy. Source
INB03 — A product candidate targeting the innate immune system. Source

Customer types

Clinical research organizations and pharmaceutical partners.

Suppliers, materials and equipment

Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its clinical trial materials; specific supplier names are not disclosed. Source

Business strengths to evaluate

Proprietary innate immune system reprogramming platform Source

Business risks and research considerations

History of operating losses and dependence on additional financing Source
Uncertainty of clinical trial success and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-13. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

INMB financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:: Not currently available
Stored price:: USD 1.87
Market capitalization:: 49.71M (currency not supplied)
Revenue:: USD 0.00
Net income:: USD -18.42M
Free cash flow:: USD -23.62M
Cash:: USD 18.41M
Total debt:: USD 1.41M
EPS:: USD -0.69

What stands out

Reported year-over-year revenue growth is -100.0%.
Free cash flow is USD -23.62M, negative for the stored period.
The balance sheet shows USD 18.41M of cash versus USD 1.41M of total debt, an excess of cash over debt on these two reported measures.
The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

Cash exceeds debt by USD 17.01M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for INMB

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

What is driving INMB's revenue decline, and does the latest filing suggest the weakness is temporary or structural?
How long can INMB fund negative free cash flow using its current cash position before it may need more debt or new shares?
How is INMB likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
What specifically needs to improve for INMB to reach sustainable profitability?
What does the current fundamental change risk warning mean for the reliability or interpretation of INMB's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 82% of the scoring inputs required for this public page are currently available.

How to research INMB

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.